Moshkevich Solomon

SEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,444

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.60 to $150.37 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,352

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.83 to $148.47 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-011612 · form4-04302025_090407.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,205

F2 · shares: Represents a charitable contribution by the Reporting Person.

SEC source: 0001415889-25-011612 · form4-04302025_090407.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,280

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023 and January 26, 2024.

SEC source: 0001415889-25-011192 · form4-04222025_090404.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,486

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022.

SEC source: 0001415889-25-011192 · form4-04222025_090404.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,490

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 28, 2022.

SEC source: 0001415889-25-010103 · form4-04032025_080401.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,782

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.38 to $142.41 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-010103 · form4-04032025_080401.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,221

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.27 to $141.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-010103 · form4-04032025_080401.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,491

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.25 to $140.18 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-008660 · form4-03192025_090304.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,782

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 12, 2025.

SEC source: 0001415889-25-008660 · form4-03192025_090304.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,785

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on March 12, 2025.

SEC source: 0001415889-25-008169 · form4-03142025_090309.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,808

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs were fully-vested at the time of issuance.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-007467 · form4-03072025_090305.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,768

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.74 to $145.41 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-007467 · form4-03072025_090305.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,168

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.68 to $144.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-007467 · form4-03072025_090305.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,868

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.58 to $143.39 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-007467 · form4-03072025_090305.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 148,568

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.57 to $142.52 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-003418 · form4-02072025_090205.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,768

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and January 28, 2022, respectively.

SEC source: 0001415889-25-003418 · form4-02072025_090205.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,400

F3 · shares: On January 28, 2022, the Reporting Person was granted RSUs covering 6,087 shares of Common Stock which vest upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On February 5, 2025, the achievement of criteria was certified for the vesting of RSUs covering 1,522 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-003418 · form4-02072025_090205.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,878

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On February 5, 2025, the achievement of criteria was certified for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-003074 · form4-02042025_090204.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,203

F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on January 31, 2026 and the remaining RSUs vest in 12 equal quarterly installments thereafter.r.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-002623 · form4-01312025_090106.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,483

F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 26, 2024.

SEC source: 0001415889-25-002623 · form4-01312025_090106.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,486

F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 26, 2024.

SEC source: 0001415889-25-002623 · form4-01312025_090106.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,056

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023.

SEC source: 0001415889-25-002082 · form4-01242025_090103.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,684

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 22, 2021, January 28, 2022, June 10, 2022, and January 27, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.90 to $171.97 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-002082 · form4-01242025_090103.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,746

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 22, 2021, January 28, 2022, June 10, 2022, and January 27, 2023.

SEC source: 0001415889-25-001834 · form4-01212025_090108.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,545

F4 · shares: On June 10, 2022, the Reporting Person was granted a performance-based RSU award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 9,620 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001834 · form4-01212025_090108.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,925

F3 · shares: On January 27, 2023, the Reporting Person was granted a performance-based RSU award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 29,798 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-25-001834 · form4-01212025_090108.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,127

F1 · shares: On January 28, 2022, the Reporting Person was granted a performance-based Restricted Stock Unit ("RSU") award which vests upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 16, 2025, the achievement of milestones was certified resulting in the vesting of all such RSUs.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria.

SEC source: 0001415889-24-030118 · form4-12232024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,706

F1 · shares: Represents a charitable contribution by the Reporting Person.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,997

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,420

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,423

F4 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on October 22, 2021 and August 30, 2024, respectively.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,425

F3 · shares: On August 30, 2024, the Reporting Person was granted RSUs covering 3,044 shares of Common Stock which vest upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On December 20, 2024, the criteria was satisfied for the vesting of RSUs covering 3,044 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-24-030182 · form4-12262024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,381

F1 · shares: On October 22, 2021, the Reporting Person was granted Restricted Stock Units ("RSUs") covering 10,000 shares of Common Stock which vest in tranches upon the achievement of certain milestones relating to a combination of the passage of time and certain business performance criteria. On December 20, 2024, the criteria was satisfied for the vesting of RSUs covering 1,675 shares of Common Stock.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-24-030118 · form4-12232024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,787

F1 · shares: Represents a charitable contribution by the Reporting Person.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · derivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,323 shares

Expires 2025-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options shares are fully exercisable.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · derivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,752 shares

Expires 2025-03-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options shares are fully exercisable.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,912

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the exercise of options and in compliance with Rule 10b5-1.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.5937 to $166.5938 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,770

SEC source: 0001415889-24-029036 · form4-12112024_091201.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,447

SEC source: 0001415889-24-025808 · form4-10302024_091006.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,695

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.

SEC source: 0001415889-24-025598 · form4-10232024_091005.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,891

F3 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 22, 2021.

SEC source: 0001415889-24-025598 · form4-10232024_091005.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,147

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 28, 2022.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.6750 to $120.7600 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-020485 · form4-07312024_090710.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,441

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.

SEC source: 0001415889-24-020010 · form4-07232024_090711.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,637

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 22, 2021 and January 28, 2022.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.9850 to $105.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-014957 · form4-05302024_090507.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,186

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on June 10, 2022.

SEC source: 0001415889-24-011943 · form4-05012024_090513.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,833

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023.

SEC source: 0001415889-24-011405 · form4-04232024_090418.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,029

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 22, 2021 and January 28, 2022, respectively.

SEC source: 0001415889-24-011082 · form4-04172024_090404.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,560

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.73 to $91.48 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-011082 · form4-04172024_090404.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,049

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.73 to $90.72 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.